by admin | Oct 29, 2021 | News
Abstract Circular tandem repeat proteins (‘cTRPs’) are de novo designed protein scaffolds (in this and prior studies, based on antiparallel two-helix bundles) that contain repeated protein sequences and structural motifs and form closed circular structures. They can...
by admin | Oct 12, 2021 | News
Our industry’s response to COVID-19 defied the conventional wisdom that it takes years to deliver new drugs. Makers of monoclonal antibodies led the pack, most notably Regeneron (NSDQ:REGN), which manufactured the 8-g, two-antibody cocktail administered to...
by admin | Oct 6, 2021 | News
By Brian Finrow and Jim Roberts Today, Lumen announced significant new federal funding covering a Phase 2 clinical trial of our Covid-19 product, LMN-301. It is, we believe, the world’s first clinical program directed specifically at the GI manifestations of Covid-19....
by admin | Sep 22, 2021 | News
Listen now
by admin | Aug 27, 2021 | News
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian...
by admin | Aug 11, 2021 | News
Today Lumen announced the first results of our long-running collaboration with Google’s world-beating AI/ML (machine learning) team. The gist: advanced algorithms helped us navigate a dizzying amount of data to double the productivity of cGMP biologics manufacturing...
4 ideas to kick-start U.S. drug research — and beat China in biotech
Revolutionizing the Production of Biologics with Algae
Past Wilkes Prize winners accelerate audacious climate solutions
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota